Veraxa Biotech AG

Veraxa Biotech AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Zurich, Zuerich. The company went IPO on 2026-06-11. Veraxa Biotech AG is a Switzerland-based Company that develops antibody-based therapeutics for the treatment of cancer. The firm focuses on advancing proprietary platform technologies designed to generate targeted oncology therapies with improved safety and efficacy profiles. Its approach originates from scientific discoveries at the European Molecular Biology Laboratory, supporting the development of next-generation antibody-based drug candidates. The firm aims to expand treatment options for solid tumors by enabling more precise targeting mechanisms and potentially broader therapeutic windows compared with conventional therapies, addressing unmet needs across oncology markets through platform-driven innovation.